Open AccessCardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
Author(s) -
Silvio E. Inzucchi,
Kamlesh Khunti,
David Fitchett,
Christoph Wanner,
Michaela Mattheus,
Jyothis T. George,
Anne Pernille Ofstad,
Bernard Zinman
Publication year - 2020
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/clinem/dgaa321
Subject(s) - empagliflozin , empa , medicine , cardiology , outcome (game theory) , risk factor , diabetes mellitus , type 2 diabetes , endocrinology , economics , chemistry , mineralogy , mathematical economics , electron microprobe
Control of multiple cardiovascular (CV) risk factors reduces CV events in individuals with type 2 diabetes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom